Proceeds from the loan facility will go toward the acquisition of Envigo's nonclinical research services business and other general corporate purposes.
The company is commercializing a method developed by researchers at Johns Hopkins that detects cancer with high specificity from a blood sample.
The company plans to use the funds to support further commercialization of its tumor tissue sequencing test, the Paradigm Cancer Diagnostic.
The firm will use the proceeds to scale operations, advance its companion diagnostics program, and further expand its minimal residual disease program.
The direct-to-consumer at-home health testing firm intends to use the funds to expands its platform development and supply logistics in North America.
The firm will use the proceeds to further a validation study tracking the ability of its cell culture assay to predict patient response to cancer therapies.
Specific Diagnostics said that the CARB-X funding will enable it to prepare its AST instrument for clinical trials and regulatory validation.
The company will use the money to launch its first product, Unity, a noninvasive prenatal test for recessively inherited single-gene disorders.
Funds raised will help accelerate commercialization of the firm's InVisionFirst-Lung liquid biopsy test and support development of the firm's platform for new indications
The company said it will use part of the proceeds to repurchase some of its senior notes due in January 2025, and the rest for corporate purposes.